Brokerage firm JP Morgan Downgrades its rating on Esperion Therapeutics Inc(NASDAQ:ESPR). In a research note issued to the investors, the brokerage major Lowers the price-target to $15.00 per share. The shares have been rated Neutral. Previously, the analysts had a Overweight rating on the shares. The rating by JP Morgan was issued on Jun 29, 2016.
Esperion Therapeutics Inc (ESPR) made into the market gainers list on Fridays trading session with the shares advancing 4.76% or 0.47 points. Due to strong positive momentum, the stock ended at $10.35, which is also near the day’s high of $10.5. The stock began the session at $10.15 and the volume stood at 15,66,097 shares. The 52-week high of the shares is $100.98 and the 52 week low is $9.58. The company has a current market capitalization of $233 M and it has 2,25,41,028 shares in outstanding.
Esperion Therapeutics Inc(ESPR) last announced its earnings results on May 4, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-0.65. Analysts had estimated an EPS of $-0.74.
Several Insider Transactions has been reported to the SEC. On May 5, 2016, Timothy M Mayleben (CEO) purchased 7,000 shares at $14.85 per share price.Also, On Mar 2, 2016, Gilbert S Omenn (director) purchased 5,000 shares at $15.28 per share price.On Apr 27, 2015, Dov A Md Goldstein (director) sold 217,469 shares at $107.73 per share price, according to the Form-4 filing with the securities and exchange commission.
Esperion Therapeutics Inc. is a pharmaceutical company focused on developing and commercializing oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Company’s primary activities include conducting research and development activities including nonclinical preclinical and clinical testing performing business and financial planning recruiting personnel and raising capital. ETC-1002 the Company’s lead product candidate is an orally available once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.